Supplementary Table 1. Baseline characteristics of study subjects.
| All N = 1,064 |
Male N = 752 |
Female N = 312 |
P value | |
|---|---|---|---|---|
| Age, years | 58.18 ± 9.74 | 57.59 ± 9.87 | 59.62 ± 9.29 | 0.002 |
| Hypercholesterolemia, n (%) | 236 (22.2) | 160 (21.3) | 76 (24.4) | 0.313 |
| Hypertension, n (%) | 331 (31.1) | 266 (35.4) | 65 (20.8) | < .001 |
| Former smoker, n (%) | 106 (10) | 101 (13.5) | 5 (1.6) | < 0.05 |
| Current smoker, n (%) | 234 (22.2) | 223 (29.9) | 11 (3.6) | < 0.05 |
| Statin use, n (%) | 265 (24.9) | 186 (24.8) | 79 (25.3) | 0.911 |
| BMI, Kg/m2 | 24.86 ± 3.23 | 25.41 ± 3.00 | 23.53 ± 3.37 | < .001 |
| SBP, mmHg | 123.61 ± 16.81 | 124.90 ± 16.11 | 120.49 ± 18.03 | < .001 |
| DBP, mmHg | 78.21 ± 9.99 | 79.81 ± 9.63 | 74.34 ± 9.79 | < .001 |
| LVEF, % | 62.31 ± 7.32 | 62.38 ± 7.29 | 62.16 ± 7.40 | 0.695 |
| Framingham 10-year risk, % | 17.38 ± 13.31 | 21.41 ± 13.50 | 7.59 ± 5.41 | < .001 |
| HbA1c, % | 5.67 ± 0.31 | 5.67 ± 0.32 | 5.65 ± 0.27 | 0.139 |
| Glucose, mg/dL | 91.17 ± 9.07 | 91.45 ± 9.27 | 90.50 ± 8.56 | 0.106 |
| eGFR, mL/min/1.73 m2 | 82.12 ± 14.22 | 82.21 ± 15.21 | 81.89 ± 11.50 | 0.713 |
| Uric Acid, mg/dL | 6.55 ± 1.59 | 7.01 ± 1.50 | 5.44 ± 1.21 | < .001 |
| Cholesterol, mg/dL | 91.17 ± 9.07 | 91.45 ± 9.27 | 90.50 ± 8.56 | 0.106 |
| TG, mg/dL | 127.89 ± 73.95 | 137.07 ± 91.22 | 146.40 ± 75.47 | 0.007 |
| HDL-C, mg/dL | 47.79 ± 13.08 | 43.99 ± 10.50 | 56.99 ± 14.10 | < .001 |
| LDL-C, mg/dL | 130.05 ± 33.61 | 128.71 ± 34.02 | 133.29 ± 32.44 | 0.043 |
Data are mean ± SD or n (%).SIS indicates segment involvement score; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; LVEF, left ventricular ejection fraction; HbA1c, hemoglobin A1c; eGFR, estimated Glomerular filtration; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol